RTTNews — Definium Therapeutics, Inc. (DFTX) has priced a public offering of 20.59 million common shares at $34 per share, generating gross proceeds of approximately $700 million. The transaction is slated to close on or about June 25, 2026.
The company granted the underwriters a 30‑day option to purchase up to an additional 3.08 million shares at the same offering price, net of discounts and commissions.
Definium’s lead investigational candidate, DT120, is an orally disintegrating tablet (ODT) derived from lysergide (LSD). It is currently in Phase 3 trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD). Recent Phase 3 “Emerge” study results for DT120 in MDD demonstrated meeting both primary and all key secondary efficacy endpoints.
Additional Phase 3 data releases for DT120 ODT are anticipated in the coming months, covering the Voyage and Panorama trials in GAD.
Net proceeds from the offering will be allocated to research and development activities, preparation for potential FDA commercialization of DT120 ODT, and working capital for general corporate purposes.
Lead bookrunners for the offering include J.P. Morgan, Jefferies, Leerink Partners, and BofA Securities, with Evercore ISI and Stifel also acting as bookrunners.
As of March 31, 2026, Definium held $373.4 million in cash and cash equivalents.
DFTX shares have traded in a 52‑week range of $6.40 to $39.16. The stock closed Tuesday at $36.18, down 1.34%, but was up 0.86% in after‑hours trading at $36.49.
